Patrick Yeramian
Corporate Officer/Principal bij Dlx Therapeutics L L C
Vermogen: 583 918 $ op 31-03-2024
Profiel
Patrick D.
Yeramian is currently the General Manager at Dlx Therapeutics L L C.
Previously, he worked as a Medical Director at Pfizer Inc., Marker Therapeutics, Inc., Vaccine & Gene Therapy Institute of Florida Corp., Kantum Pharma, Inc., and Tapimmune, Inc. He also served as the Director-Clinical Research at G.D.
Searle LLC and as the Chief Medical Officer at Viragen, Inc. and BioVie, Inc. Additionally, he is currently the Chief Medical Officer & Global Head-Clinical R&D at Amylyx Pharmaceuticals, Inc. Dr. Yeramian holds a graduate degree from Université de Paris XI Paris Sud, a doctorate from Universite Paris Est.
Creteil Val De Marne, and an MBA from Rutgers Business School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 09-01-2024 | 205 605 ( 0.30% ) | 583 918 $ | 31-03-2024 |
Actieve functies van Patrick Yeramian
| Bedrijven | Functie | Begin |
|---|---|---|
| Dlx Therapeutics L L C | Corporate Officer/Principal | 01-01-2018 |
Eerdere bekende functies van Patrick Yeramian
| Bedrijven | Functie | Einde |
|---|---|---|
| AMYLYX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 28-11-2023 |
| BIOVIE INC. | Chief Tech/Sci/R&D Officer | 01-11-2021 |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Chief Tech/Sci/R&D Officer | 01-03-2019 |
| MARKER THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2017 |
| Tapimmune, Inc. | Chief Tech/Sci/R&D Officer | 01-01-2017 |
Opleiding van Patrick Yeramian
| Universite Paris Est Creteil Val De Marne | Doctorate Degree |
| Rutgers Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| MARKER THERAPEUTICS, INC. | Health Technology |
| BIOVIE INC. | Health Technology |
| AMYLYX PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Health Technology |
| Université de Paris XI Paris Sud | Consumer Services |
| G.D. Searle LLC | |
Vaccine & Gene Therapy Institute of Florida Corp.
 Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Vaccine & Gene Therapy Institute of Florida Corp. provides research services. The non-profit company is based in Port Saint Lucie, FL. | Commercial Services |
Kantum Pharma, Inc.
Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Commercial Services |
| Dlx Therapeutics L L C | |
| Tapimmune, Inc. |
